Who Owns Biomea Fusion Company?

Biomea Fusion Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Calls the Shots at Biomea Fusion?

Understanding the ownership structure of a biotech company is crucial for investors and stakeholders alike. Biomea Fusion, a clinical-stage biopharmaceutical company, recently pivoted its focus to diabetes and obesity medicines. This shift, coupled with the Biomea Fusion SWOT Analysis, makes understanding its ownership more important than ever.

This analysis of Biomea Fusion ownership will explore the company’s evolution from its founding in 2017 to its present-day structure. We'll examine the key stakeholders, including the company executives, and how their influence shapes Biomea Fusion's strategic direction and future prospects. The insights provided will help you understand the dynamics of this pharmaceutical company and its position in the market.

The story of Biomea Fusion begins in 2017, co-founded by Thomas Butler and Ramses Erdtmann. Their shared vision centered on developing targeted therapies for genetically defined cancers and metabolic diseases. This biotech company aimed to create a platform of irreversible inhibitors, leveraging their collective experience in precision oncology.

Thomas Butler took on the roles of Chief Executive Officer and Chairman of the Board, while Ramses Erdtmann served as President and Chief Operating Officer. Their previous collaboration at Pharmacyclics provided a strong foundation for their new venture. The founders brought a wealth of experience to Biomea Fusion, setting the stage for its early development and strategic direction.

While the exact initial equity splits aren't public, the impact of the founders is evident in their current shareholdings. The initial investments were crucial in expanding the team and advancing the research.

Founders' Roles

Thomas Butler served as CEO and Chairman, while Ramses Erdtmann was President and COO. Their roles were pivotal in shaping the company's early strategy and operations. They brought experience from their collaboration at Pharmacyclics.

Initial Vision

The primary goal was to develop targeted therapies for cancers and metabolic diseases. This focus drove the creation of a platform of irreversible inhibitors. Their expertise in precision oncology was a key asset.

Early Investors

Early backers included Cormorant Asset Management, Boxer Capital, and Janus Henderson Investors. These investments were vital for expanding the research team. They also helped advance preclinical and clinical capabilities.

Shareholder Details

Thomas Butler holds 4.68 million shares, representing 12.45%. Ramses Erdtmann holds 985,347 shares, accounting for 2.62%. These holdings highlight their significant stake in the company.

Key Shareholders and Their Impact

The early investors played a crucial role in the growth of Biomea Fusion. Their financial support enabled the company to expand its team and advance its research programs. Understanding the Biomea Fusion ownership structure provides insights into the company's strategic direction and financial stability. For additional insights, you can read more about the Growth Strategy of Biomea Fusion.

• Thomas Butler's significant shareholding indicates his continued commitment.
• Ramses Erdtmann's stake reflects his ongoing involvement in the company's success.
• Early investments from leading firms helped Biomea Fusion achieve its milestones.
• The company's structure is designed to support its drug development pipeline.

Biomea Fusion SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The journey of Biomea Fusion, a biotech company, into the public market began on April 16, 2021, through an Initial Public Offering (IPO). This event was a pivotal moment, raising $153 million and establishing an initial market capitalization of $489.05 million. Since then, the company's market capitalization has seen fluctuations. As of June 12, 2025, the market cap stood at $98.06 million, reflecting a decrease of 79.95% since its IPO. This shift has significantly impacted the company's ownership structure and investor confidence.

The ownership of Biomea Fusion, a pharmaceutical company, is distributed among institutional investors, retail investors, and individual shareholders. As of May 2025, institutional investors collectively held approximately 56.07% of the shares. Mutual funds, a segment within institutional investors, have slightly decreased their holdings from 34.86% to 34.82% during May 2025. Other data indicates a slightly different distribution, with approximately 37.37% of the stock owned by Institutional Investors, 9.66% by Insiders, and 52.97% by Public Companies and Individual Investors. Another source suggests 15.30% institutional ownership, 9.66% insider ownership, and 52.97% retail investor ownership. These varying figures highlight the dynamic nature of ownership and the influence of different investor groups.

Major institutional shareholders play a crucial role in shaping the direction of Biomea Fusion. As of March 30, 2025, FMR LLC was the largest shareholder, holding 14.47% of the shares, equivalent to 5,435,803 shares. Cormorant Asset Management, LP held 9.50% (3,570,872 shares), and BlackRock, Inc. held 5.75% (2,159,991 shares). Other significant institutional holders include The Vanguard Group, Inc., Aisling Capital Management LP, Geode Capital Management, LLC, State Street Global Advisors, Inc., and Federated Hermes, Inc. Bihua Chen, an insider, is noted as owning the most shares among company executives, with 3,570,872 shares, representing 9.50% of the company. Understanding the ownership structure is key to understanding the Growth Strategy of Biomea Fusion.

Key Takeaways on Biomea Fusion Ownership

The ownership of Biomea Fusion, a biotech company, is a mix of institutional and retail investors.

• Institutional investors hold a significant portion of the shares.
• Major shareholders include FMR LLC, Cormorant Asset Management, and BlackRock, Inc.
• Company executives also hold shares, influencing the company structure.
• The stock price and market capitalization have seen fluctuations since the IPO.

Biomea Fusion PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors of Biomea Fusion, a biotech company, is pivotal in guiding the company's strategy and operations. The board is structured into three classes, with each director serving a three-year term. This staggered system ensures continuity, as only a portion of the board is up for election each year. As of April 14, 2025, the company had 37,572,250 shares of common stock outstanding, each carrying one vote, which is crucial for understanding Biomea Fusion ownership and voting power.

The Class I directors, whose terms expire in 2025, include Bihua Chen, Elizabeth Faust, and Sumita Ray. Rainer (Ramses) Erdtmann, serving as President and COO, is a Class II director with a term expiring in 2026. Eric Aguiar, M.D., holds the position of Lead Independent Director. Furthermore, Michael J. M. Hitchcock, Ph.D., appointed Interim Chief Executive Officer in March 2025, is a board member whose term expires in 2027. This leadership structure is designed to ensure experienced oversight of the pharmaceutical company.

The company's governance structure includes provisions that could potentially delay or prevent changes in control. These include a classified board, the board's authority over director appointments, and the requirement of a two-thirds stockholder vote for director removal under specific circumstances. Additionally, certain actions, such as amending specific provisions of the certificate of incorporation, require a 66-2/3% vote from the outstanding voting stock. Understanding the board of directors and their influence is vital when considering the target market of Biomea Fusion.

Voting Power and Governance at Biomea Fusion

The board's structure and voting rights significantly impact the company's strategic direction. The staggered terms of the directors provide stability. The voting power is concentrated among the shareholders, with each share holding one vote.

• Classified Board: Staggered terms for directors.
• Shareholder Voting: One vote per share.
• Director Removal: Requires a two-thirds stockholder vote.
• Amendments: Certain actions require a 66-2/3% vote.

Biomea Fusion Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Biomea Fusion, a biotech company, has undergone significant shifts in its ownership structure and strategic direction. A key move in January 2025 saw the company pivot its focus to diabetes and obesity medicines, discontinuing internal development of its oncology programs. This strategic shift led to a workforce reduction of approximately 35% and the consolidation of operations to a single facility in San Carlos, California, aimed at optimizing operating expenses and extending its cash runway into the fourth quarter of 2025.

Leadership changes also marked this period. In March 2025, Thomas Butler stepped down as CEO and board member, with Mick Hitchcock, Ph.D., appointed as interim Chief Executive Officer. Dr. Hitchcock's appointment, effective immediately, is intended to leverage his extensive experience in late-stage development, regulatory strategy, and commercialization to guide Biomea Fusion's metabolic pipeline. These adjustments reflect the dynamic nature of the pharmaceutical company and its ongoing efforts to adapt to market demands and advance its drug development pipeline.

Institutional ownership remains a critical factor in understanding who owns Biomea Fusion. As of recent filings, 213 institutional owners held a total of 23,283,224 shares. While institutional holdings remained relatively stable at 56.07% in May 2025, mutual funds slightly decreased their positions to 34.82% during the same period. Despite market volatility, institutional investors have increased their positions, and analysts maintain a 'strong buy' consensus, with a 12-month target price of $22.30 as of May 2025. The company's 2024 annual report was filed on March 31, 2025.

Key Ownership Trends

Institutional investors continue to hold a significant portion of Biomea Fusion shares, indicating confidence in the company's long-term prospects. The slight decrease in mutual fund holdings may reflect portfolio adjustments or shifts in investment strategies.

Impact of Strategic Changes

The company's strategic focus on diabetes and obesity, along with leadership changes, is designed to streamline operations and improve financial performance. These moves are crucial for extending the cash runway and advancing its drug pipeline.

Biomea Fusion Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs